JD HEALTH
06618
BIDU-SW
09888
JD-SW
09618
ALI HEALTH
00241
BEKE-W
02423
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 5.94%3.77B | -71.35%5.34B | -64.27%3.56B | -8.63%18.64B | 9.18%9.97B | 63.80%20.4B | 36.22%9.13B | 44.75%12.45B | 345.86%6.7B | 27.71%8.6B |
Operating income | 5.94%3.77B | -71.35%5.34B | -64.27%3.56B | -8.63%18.64B | 9.18%9.97B | 63.80%20.4B | 36.22%9.13B | 44.75%12.45B | 345.86%6.7B | 27.71%8.6B |
Cost of sales | -24.92%-4.04B | 77.20%-4.77B | 63.39%-3.23B | -33.97%-20.94B | -28.54%-8.83B | -62.18%-15.63B | -29.50%-6.87B | -70.66%-9.64B | -505.88%-5.3B | -29.90%-5.65B |
Operating expenses | -24.92%-4.04B | 77.20%-4.77B | 63.39%-3.23B | -33.97%-20.94B | -28.54%-8.83B | -62.18%-15.63B | -29.50%-6.87B | -70.66%-9.64B | -505.88%-5.3B | -29.90%-5.65B |
Gross profit | -179.10%-262.1M | 124.48%564.66M | -71.03%331.36M | -148.44%-2.31B | -49.49%1.14B | 69.33%4.76B | 61.65%2.26B | -4.79%2.81B | 122.98%1.4B | 23.72%2.95B |
Selling expenses | 55.73%-94.74M | 37.24%-477.15M | 41.78%-213.99M | 28.91%-760.26M | 30.57%-367.53M | -43.93%-1.07B | -113.98%-529.34M | -65.58%-743.04M | -42.46%-247.38M | -144.54%-448.74M |
Administrative expenses | 29.29%-205.85M | 37.63%-541.65M | 35.64%-291.11M | 10.53%-868.4M | 2.03%-452.33M | -18.69%-970.59M | -30.38%-461.7M | -58.27%-817.77M | -43.40%-354.11M | -21.80%-516.7M |
Revaluation surplus | ---- | 5.18%-338.86M | ---- | -242.44%-357.38M | -103.78%-7.96M | 9,527.97%250.91M | 12,774.37%210.5M | -97.93%2.61M | -98.52%1.64M | 49.88%126.16M |
-Changes in the fair value of investment property | ---- | 5.18%-338.86M | ---- | -242.44%-357.38M | -103.78%-7.96M | 9,527.97%250.91M | 12,774.37%210.5M | -97.93%2.61M | -98.52%1.64M | 49.88%126.16M |
Impairment and provision | -65.50%-13.81M | 92.26%-44.22M | ---8.34M | -7,568.00%-571.11M | ---- | ---7.45M | ---- | ---- | ---- | ---- |
-Other impairment is provision | -65.50%-13.81M | 92.26%-44.22M | ---8.34M | -7,568.00%-571.11M | ---- | ---7.45M | ---- | ---- | ---- | ---- |
Special items of operating profit | -187.74%-46.8M | 49.48%-297.81M | 148.69%53.34M | -186.02%-589.54M | -122.48%-109.54M | -4.73%685.35M | 65.88%487.23M | 61.58%719.36M | 18.62%293.72M | 79.17%445.19M |
Operating profit | -384.15%-623.3M | 79.19%-1.14B | -162.37%-128.74M | -249.35%-5.45B | -89.53%206.42M | 85.00%3.65B | 80.06%1.97B | -22.90%1.97B | 93.63%1.09B | 21.18%2.56B |
Financing income | -77.66%3.7M | -88.51%31.52M | -92.40%16.56M | 16.01%274.41M | 310.24%217.93M | 57.85%236.53M | -14.65%53.12M | 22.34%149.85M | -2.62%62.24M | 28.90%122.49M |
Financing cost | -116.91%-34.11M | -152.68%-162.98M | -68.86%-15.73M | -231.13%-64.5M | 5.83%-9.31M | 17.90%-19.48M | 20.87%-9.89M | -18.74%-23.73M | -37.53%-12.5M | 72.12%-19.98M |
Special items of earning before tax | -301.29%-20.9M | 120.07%41.41M | 62.37%-5.21M | -1,654.82%-206.35M | 49.34%-13.84M | -144.58%-11.76M | -67.26%-27.33M | 222.44%26.38M | 37.13%-16.34M | -127.81%-21.55M |
Earning before tax | -406.79%-674.62M | 77.52%-1.23B | -133.18%-133.12M | -241.31%-5.45B | -79.81%401.19M | 81.39%3.86B | 76.14%1.99B | -19.49%2.13B | 89.86%1.13B | 19.31%2.64B |
Tax | 151.99%43.47M | -86.37%-644.74M | 61.26%-83.62M | 74.23%-345.94M | 68.01%-215.85M | -96.40%-1.34B | -72.37%-674.81M | 37.25%-683.5M | -79.77%-391.49M | -18.79%-1.09B |
After-tax profit from continuing operations | -191.21%-631.15M | 67.74%-1.87B | -216.94%-216.73M | -330.51%-5.8B | -85.88%185.34M | 74.28%2.51B | 78.15%1.31B | -7.02%1.44B | 95.69%736.74M | 19.69%1.55B |
Earning after tax | -191.21%-631.15M | 67.74%-1.87B | -216.94%-216.73M | -330.51%-5.8B | -85.88%185.34M | 74.28%2.51B | 78.15%1.31B | -7.02%1.44B | 95.69%736.74M | 19.69%1.55B |
Minority profit | -187.14%-111.34M | 69.62%-313.89M | -29.78%127.77M | -163.37%-1.03B | -76.64%181.97M | 1,010.39%1.63B | 167.09%778.94M | -71.58%146.85M | 214.17%291.64M | 69.04%516.73M |
Profit attributable to shareholders | -50.89%-519.8M | 67.33%-1.56B | -10,322.64%-344.5M | -638.80%-4.76B | -99.37%3.37M | -31.79%883.96M | 19.87%533.52M | 25.22%1.3B | 56.91%445.09M | 4.46%1.03B |
Basic earnings per share | -50.93%-0.1464 | 67.33%-0.4381 | -10,877.78%-0.097 | -638.77%-1.341 | -99.40%0.0009 | -31.79%0.2489 | 19.87%0.1502 | 25.22%0.3649 | 56.82%0.1253 | 4.44%0.2914 |
Diluted earnings per share | -50.93%-0.1464 | 67.33%-0.4381 | -10,877.78%-0.097 | -638.77%-1.341 | -99.40%0.0009 | -31.79%0.2489 | 19.87%0.1502 | 25.22%0.3649 | 56.82%0.1253 | 4.44%0.2914 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | -- | -- | -- | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.